Doctor joins COVID-19 vaccine trial to combat mistrust in the Black community | Canada News Media
Connect with us

Business

Doctor joins COVID-19 vaccine trial to combat mistrust in the Black community

Published

 on

Racialized communities have been disproportionately affected by COVID-19 in infections and deaths, but as the vaccine provides hope for many across the world, doctors are working to combat mistrust in the COVID-19 vaccine within the Black and Indigenous communities.

One doctor in the United States took matters into her own hands, by signing up to be a part of a COVID-19 vaccine clinical trial and sharing her story online.

Dr. Valerie Fitzhugh is an Associate Professor of Pathology at Rutgers University Medical School. In a thread shared on Twitter, Fitzhugh detailed why she decided to join the trial and what it was like participating in one.

Fitzhugh tells CityNews she initially decided to research participating in a clinical trial because historically, it’s very difficult to get communities of colour to trust in medical establishments and to trust in some of these scientific developments, citing Henrietta Lacks’ story as just one example of this.

In the 1950s, researchers took a sample of cancer cells from Lacks without her permission while she was under anesthesia and found the cells could be grown indefinitely.

The so-called “HeLa” cells became crucial for understanding viruses, cancer treatments, in-vitro fertilization and development of vaccines, including the polio vaccine.

“There is a lot of mistrust, particularly in the Black community in the United States, around experimentation on black and brown bodies which happened, unfortunately, quite a lot in the earlier parts of the 19th century,” Fitzhugh said.

She had also heard that participation by people of colour in COVID-19 vaccine trials was low.

“Everything I had heard and everything I read had noted that the participation by people of colour was a lot lower than what they wanted at that time,” Fitzhugh said.

“The biggest driving force for me was representation by the Black community. I felt like doing my part and adding to that trial. Giving a little bit something of myself for the greater good made it so worth it.”

A study on race and health conducted by Kaiser Family Foundation in the U.S. found that Black adults were less likely than any other groups to get a COVID-19 vaccine. Just 17 per cent of Black adults said they would definitely get the vaccine and 27 per cent said they would definitely not get it.

Fitzhugh said by sharing her story, she hoped to open up an important discussion within the Black community about getting the COVID-19 vaccine.

Since tweeting on Dec. 12, her story has been retweeted almost 10,000 times.

“I want people to be educated. You have to trust the process and trust the science. If I at least tell my story and tell what I went though, it may give people an idea what to expect, should they get vaccinated,” Fitzhugh said.

Dr. Fitzhugh could not disclose the trial she is participating in, but said she received her first dose in October and second in November. She doesn’t know if she received a placebo or the actual vaccine at this point.

Dr. Fitzhugh says she could be “unblinded” soon and find out whether she has been vaccinated. She’s currently eligible to receive the Pfizer-BioNTech vaccine through her work as a physician, but doesn’t want to take the vaccine away from another doctor or hospital worker if it is not necessary.

“I’m tired of seeing people who look like me die of this disease.”

“What I find to be so important now is that we have these discussions, we openly discuss why the hesitancy is there, why the mistrust is there so that we can have educated conversations going forward about people at least considering being vaccinated,” Dr. Fitzhugh said. “I don’t think trying to convincing people to be vaccinate is the appropriate approach. We need to have the conversations, acknowledge the hesitancy and why it’s there.”

Fitzhugh says hearing so many stories and seeing the pain of those who have been affected by the COVID-19 pandemic made it all the more important to become apart of the trial.

“I’m tired of seeing people who look like me die of this disease.”

“I hope people at least consider being vaccinated. I do want people to get the information that’s available. I want people to talk to their physicians…and ask the difficult questions,” she said.

Gerald Evans, the Chair for Infection Diseases at Queen’s University, says there is a clear difference between those who are hesitant to receive a vaccine and so-called “anti-vaxxers.”

“It isn’t anti-vaxxer at all. There is an intrinsic hesitancy when you think to yourself ‘Were there enough people who are like me enrolled in these studies so I can be confident about the data?’ Over history, there has been a significant disadvantage amongst people who were not white in scientific studies,” Evans said.

With most of the data around vaccine hesitancy and mistrust coming from the U.S., Evans said they are making a push to collect similar data in Canada as vaccine rollout plans continue to be formulated.

“I know that there is a big move to make sure we do the same move here in Canada, getting away from just general polling information and really understanding within these communities what is the feeling about taking the vaccine,” Evans said.

Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version